| Document |
Document Title |
|
WO/2023/174351A1 |
Disclosed in the present invention are a pyrrole amide compound, and a preparation method therefor and the use thereof. The structure of the compound is as represented by formula (I). The compound is a brand-new anti-HBV compound. Furthe...
|
|
WO/2023/176867A1 |
[Problem] To develop a new method for producing 2-acetyl-1-pyrroline. [Solution] 2-acetyl-1-pyrroline can be favorably produced through the step of reacting N-(tert-butoxycarbonyl)-L-proline with N,O-dimethylhydroxylamine. The reaction s...
|
|
WO/2023/173203A1 |
Provided herein is a method for a method for producing an ionizable amino lipid, or a pharmaceutically acceptable salt thereof, the method comprising a nucleophilic displacement of a leaving group L in a compound of Formula (II), wherein...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/171801A1 |
Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentia...
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/164201A1 |
A compound which is useful as a STING inhibitor is provided. The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory a...
|
|
WO/2023/164118A1 |
Compounds according to formula I: wherein Ar is an aryl or heteroaryl group, A is a C1-C3 alkyl, Z and Y are independently C1-C3 alkylene, X is C1-C3 alkylene, and R1-R5 are selected from -H, halogen, C1-C3 alkyl, or phenyl, or a pharmac...
|
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|
|
WO/2023/160702A1 |
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a ...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/154412A1 |
Pharmaceutical compounds have anti-inflammatory activity and are capable of reducing the levels of substance P(SP), calcitonin gene-related peptide (CGRP), glutamate, or a combination thereof. A pharmaceutical composition may include a t...
|
|
WO/2023/152182A1 |
Present invention relates to a compound according to formula (II): and all stereoisomers, racemic mixtures, tautomers, pharmaceutically acceptable salts, prodrugs, hydrates, solvates and polymorphs thereof, as well as pharmaceutical comp...
|
|
WO/2023/152415A1 |
The present invention relates to a compound of formula I, wherein the groups R1 to R5 and Cy have the meaning described in the description, for use thereof in the treatment and/or prevention of an infection or disease caused by the infec...
|
|
WO/2023/154519A1 |
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/149487A1 |
The present invention pertains to a method for producing a pyrrole-imidazole polyamide, the method comprising the following steps A1 and A2. Step A1: A reduction step for reducing compound 1 to obtain compound 2; Step A2: An extension st...
|
|
WO/2023/146785A1 |
The present disclosure provides compounds of the formula (III) and their pharmaceutically acceptable salts, and compounds of the formula (IV) and their pharmaceutically acceptable salts, and pharmaceutical compositions comprising these c...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/142600A1 |
The present invention relates to an ionizable amino lipid represented by formula (I) or a pharmaceutically acceptable salt thereof. The amino lipid can be used to deliver nucleic acids and small molecule drugs and has two ester bonds, wh...
|
|
WO/2023/143320A1 |
The present disclosure relates to the technical field of medicines. Specifically, the present disclosure relates to a compound as shown in formula (I), a linker as shown in formula (II), and a use of the compound as shown in formula (I) ...
|
|
WO/2023/146816A1 |
The present disclosure provides novel 4-substituted-phenyl acetamide and arylurea derivatives that act as agonists against GPR88. The compounds of the present disclosure are believed to be useful for the treatment of diseases and conditi...
|
|
WO/2023/137876A1 |
The present invention relates to a method for preparing a deuterated pharmaceutical intermediate D by means of using a boron-deuterium reducing agent. The method has a mild reaction route condition, high yield and abundance of deuterium,...
|
|
WO/2023/137874A1 |
A method for preparing a deuterated pharmaceutical intermediate D. The method has a mild reaction route condition, a high conversion rate and high selectivity, a high reaction yield, high reaction efficiency and high abundance of deuteri...
|
|
WO/2023/136277A1 |
According to the present invention, a protease inhibitor contains, as an active ingredient, a compound represented by general formula (I). In general formula (I), R11 and R12 each independently represent a hydrogen atom or a group repres...
|
|
WO/2023/134677A1 |
The present application relates to a method for preparing a pyrrole compound and an intermediate thereof. The pyrrole compound and/or the intermediate thereof can be used for preparing a pyrrole amide compound serving as a mineralocortic...
|
|
WO/2023/135329A1 |
Disclosed herein is a compound or pharmaceutically acceptable salt thereof of formula (I) wherein Y is a C3-11 cycloalkyl and Z is straight-chain or branched C1-14 alkyl, wherein one or more CH2 groups may independently be replaced by -(...
|
|
WO/2023/134733A1 |
High penetration prodrugs (HPPs), pharmaceutical compositions and methods thereof, for treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections are disclosed. The HPPs are capable of pene...
|
|
WO/2023/134730A1 |
The present invention provides a pyrrolidine compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and a use thereof as a coronavirus 3CL protease inhibitor in the prevention or treatment of related diseases...
|
|
WO/2023/135305A1 |
The disclosure relates to lipidic compounds of formula (I): A-(CH2)n-CX-B-Z-R1 (I) wherein R1 represents a lipophilic or hydrophobic tail-group, wherein R1 is an optionally substituted, branched, saturated or unsaturated, C10 to C55 hydr...
|
|
WO/2023/130117A1 |
Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are...
|
|
WO/2023/116812A1 |
The present disclosure provides a sulfonylurea compound. Specifically, provided are a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in prep...
|
|
WO/2023/121753A1 |
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...
|
|
WO/2023/116811A1 |
A short peptide compound containing β-aminoketone and the use thereof, and specifically disclosed is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/116734A1 |
Provided herein are antiviral compounds of Formula P-I or pharmaceutically acceptable salts, N-oxides, prodrugs, hydrates, or solvates thereof, pharmaceutical compositions containing the same, methods for their use, and methods for their...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/120646A1 |
The purpose of the present invention is to newly provide an amine-protecting group useful for the synthesis of a peculiar amino acid. Provided is an amine-protecting group.
|
|
WO/2023/121975A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/119110A1 |
The present invention relates to a process for the preparation of diketones and pyrrole derivatives, optionally substituted in the 2 and/or 5 positions, from furans.
|
|
WO/2023/112033A2 |
The present invention relates to various compounds, which are novel and useful intermediates in novel methods for preparation of certain compounds referred to as Saturated Targets and amorphous and crystal forms thereof, and certain mark...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114977A1 |
Described herein are compounds useful as S1PR4 receptor antagonists, pharmaceutical compositions comprising said compounds, methods of making said compounds and pharmaceutical compositions, and methods of using said compounds and pharmac...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/107563A1 |
Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases. Formula (I).
|
|
WO/2023/100110A1 |
The present invention is directed to a novel compound, (4R)-1-((S)-1-carboxypropyl)-2-oxo-4-propylpyrrolidine-3-car
boxylic acid, which can be used as an intermediate in the preparation of brivaracetam. The invention is also directed to ...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/099462A1 |
The present invention relates to amine-containing vinyldisiloxane compounds which are useful in the manufacture of elastomeric polymers that can be used in rubber articles such as tires. The present invention further relates to a process...
|
|
WO/2022/272248A9 |
The invention provides compounds, compositions thereof, and methods of using the same for the inhibition of Cbl-b, and the treatment of a variety of Cbl-b-mediated diseases, disorders or conditions, associated with modulating the immune ...
|
|
WO/2023/096512A1 |
A group of chemical compounds has been disclosed, especially for the treatment of neurological diseases, which are modified alanine derivatives whose structures has been designed based on the bioisosteric and selective replacement of hyd...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
